# Selection of laboratory assays for reliable assessment of complement-dependent cytotoxicity: impact of assay choice on CDC quantification

**Authors:** Alan Majeranowski, Grzegorz Stasiłojć, Nadia Panasiuk, Marcin Okrój

PMC · DOI: 10.3389/fimmu.2026.1786368 · Frontiers in Immunology · 2026-03-12

## TL;DR

This study compares different lab methods to measure how well the immune system kills cancer cells using a specific antibody, highlighting the pros and cons of each method.

## Contribution

The paper provides a comparative evaluation of CDC assay methods, emphasizing their reliability and potential for false results.

## Key findings

- Dye influx assays showed high sensitivity to early membrane permeabilization caused by complement activation.
- Metabolic activity assays were less reliable due to potential false-negative results from rapid cell death.
- Dye-release methods provided consistent results but were slower and more labor-intensive.

## Abstract

Complement-dependent cytotoxicity (CDC) results from cell lysis induced by the membrane attack complex (MAC), a pore-forming structure assembled at the terminal stage of the complement cascade that disrupts membrane integrity and causes osmotic cell death. Several methodological approaches are available to assess CDC efficacy in vitro, including (i) dye influx assays that report complement-mediated membrane permeabilization (e.g., propidium iodide staining), (ii) dye-release assays using preloaded fluorescent probes (e.g., calcein-AM), and (iii) assays based on cellular metabolic activity (e.g., MTT, XTT, or Alamar Blue) or ATP content (e.g., CellTiter-Glo). Because complement acts rapidly, often killing target cells within seconds to minutes, and because some staining procedures are cytotoxic or require time-consuming steps that may introduce artefacts, selecting an appropriate, high-throughput assay is not trivial. In this study, we evaluated representative methods from each assay class (dye influx, dye release, and metabolic readouts) to measure CDC triggered by the therapeutic anti-CD20 antibody rituximab in two human lymphoma cell lines expressing the CD20 antigen. Based on our findings, we discuss the strengths and limitations of each approach, with particular emphasis on their susceptibility to false-positive and false-negative results.

## Linked entities

- **Proteins:** MS4A1 (membrane spanning 4-domains A1)
- **Chemicals:** propidium iodide (PubChem CID 4939), calcein-AM (PubChem CID 390986), MTT (PubChem CID 64965), XTT (PubChem CID 497813), Alamar Blue (PubChem CID 11077), ATP (PubChem CID 5957)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}
- **Diseases:** CDC (MESH:D019966), cytotoxic (MESH:D064420), lymphoma (MESH:D008223)
- **Chemicals:** Alamar Blue (MESH:C005843), propidium iodide (MESH:D011419), CellTiter-Glo (-), MTT (MESH:C070243), rituximab (MESH:D000069283), ATP (MESH:D000255), calcein-AM (MESH:C085925)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13017253/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13017253/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC13017253/full.md

---
Source: https://tomesphere.com/paper/PMC13017253